REGULATORY

Clarify Definition of Ads to Not Hamper Info Delivery to Patients: PhRMA Tells Govt

December 21, 2018
The Pharmaceutical Research and Manufacturers of America (PhRMA) is calling on the Japanese government to clarify its definition of advertising/ads and review regulations so that they would not hamstring proper information provisioning to patients. A working group of the government’s…

To read the full story

REGULATORY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…